1.	Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 04-21, NCT01241500
2.	Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 04-22, 11PAN01, NCT01360853
3.	Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Onconova 09-05, AAAJ0151, NCT01584531
4.	Oral Rigosertib for Squamous Cell Carinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Onconova 09-09, COMIRB 13-0116, NCT01807546
5.	Phase I Pilot Study of ON 01910.Na in Patients With Refractory Anemia With Excess Blasts (RAEB)-1 or RAEB-2 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: NHLBI Protocol IDs: NHLBI-07-H-0225, 07-H-0225, NCT00533416
6.	Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011005, NCT01700335